JP7386208B2 - 抗folr1免疫抱合体投薬レジメン - Google Patents
抗folr1免疫抱合体投薬レジメン Download PDFInfo
- Publication number
- JP7386208B2 JP7386208B2 JP2021125147A JP2021125147A JP7386208B2 JP 7386208 B2 JP7386208 B2 JP 7386208B2 JP 2021125147 A JP2021125147 A JP 2021125147A JP 2021125147 A JP2021125147 A JP 2021125147A JP 7386208 B2 JP7386208 B2 JP 7386208B2
- Authority
- JP
- Japan
- Prior art keywords
- folr1
- cancer
- antibody
- composition
- immunoconjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940127121 immunoconjugate Drugs 0.000 title claims description 217
- 206010028980 Neoplasm Diseases 0.000 claims description 170
- 230000037396 body weight Effects 0.000 claims description 146
- 201000011510 cancer Diseases 0.000 claims description 119
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 70
- 229920001184 polypeptide Polymers 0.000 claims description 68
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 68
- 239000000203 mixture Substances 0.000 claims description 66
- 206010033128 Ovarian cancer Diseases 0.000 claims description 45
- 239000000427 antigen Substances 0.000 claims description 41
- 102000036639 antigens Human genes 0.000 claims description 41
- 108091007433 antigens Proteins 0.000 claims description 41
- 239000012634 fragment Substances 0.000 claims description 40
- 150000003431 steroids Chemical class 0.000 claims description 33
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 32
- 238000011282 treatment Methods 0.000 claims description 31
- 238000003364 immunohistochemistry Methods 0.000 claims description 29
- 206010061137 Ocular toxicity Diseases 0.000 claims description 27
- 206010044245 Toxic optic neuropathy Diseases 0.000 claims description 27
- 231100000327 ocular toxicity Toxicity 0.000 claims description 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 22
- 238000010186 staining Methods 0.000 claims description 21
- 230000001988 toxicity Effects 0.000 claims description 16
- 231100000419 toxicity Toxicity 0.000 claims description 16
- 101001023230 Homo sapiens Folate receptor alpha Proteins 0.000 claims description 15
- 230000014509 gene expression Effects 0.000 claims description 15
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims description 14
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 14
- 229960003957 dexamethasone Drugs 0.000 claims description 14
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 14
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 12
- 230000002829 reductive effect Effects 0.000 claims description 12
- FUHCFUVCWLZEDQ-UHFFFAOYSA-N 1-(2,5-dioxopyrrolidin-1-yl)oxy-1-oxo-4-(pyridin-2-yldisulfanyl)butane-2-sulfonic acid Chemical compound O=C1CCC(=O)N1OC(=O)C(S(=O)(=O)O)CCSSC1=CC=CC=N1 FUHCFUVCWLZEDQ-UHFFFAOYSA-N 0.000 claims description 11
- 206010014733 Endometrial cancer Diseases 0.000 claims description 11
- 230000007423 decrease Effects 0.000 claims description 11
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 10
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 8
- 206010046766 uterine cancer Diseases 0.000 claims description 8
- 229910052697 platinum Inorganic materials 0.000 claims description 7
- 230000000306 recurrent effect Effects 0.000 claims description 6
- 239000013612 plasmid Substances 0.000 claims description 5
- 230000002357 endometrial effect Effects 0.000 claims description 2
- 201000002628 peritoneum cancer Diseases 0.000 claims description 2
- 102100035139 Folate receptor alpha Human genes 0.000 claims 7
- 102000010451 Folate receptor alpha Human genes 0.000 description 257
- 108050001931 Folate receptor alpha Proteins 0.000 description 257
- 238000000034 method Methods 0.000 description 222
- 239000011230 binding agent Substances 0.000 description 200
- ZOHXWSHGANNQGO-DSIKUUPMSA-N 1-amino-4-[[5-[[(2S)-1-[[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl]oxy]-1-oxopropan-2-yl]-methylamino]-2-methyl-5-oxopentan-2-yl]disulfanyl]-1-oxobutane-2-sulfonic acid Chemical group CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)SSCCC(C(N)=O)S(O)(=O)=O)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ZOHXWSHGANNQGO-DSIKUUPMSA-N 0.000 description 169
- 210000004027 cell Anatomy 0.000 description 61
- 239000003814 drug Substances 0.000 description 61
- 229940079593 drug Drugs 0.000 description 58
- 125000005647 linker group Chemical group 0.000 description 36
- 239000000562 conjugate Substances 0.000 description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 27
- 150000001875 compounds Chemical class 0.000 description 26
- 235000001014 amino acid Nutrition 0.000 description 21
- 230000009467 reduction Effects 0.000 description 21
- 201000010099 disease Diseases 0.000 description 20
- 230000000694 effects Effects 0.000 description 20
- 230000004044 response Effects 0.000 description 19
- 230000004083 survival effect Effects 0.000 description 19
- 150000001413 amino acids Chemical class 0.000 description 18
- 208000020816 lung neoplasm Diseases 0.000 description 18
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 17
- 229940024606 amino acid Drugs 0.000 description 17
- 230000001965 increasing effect Effects 0.000 description 17
- 201000005202 lung cancer Diseases 0.000 description 17
- 108060003951 Immunoglobulin Proteins 0.000 description 16
- 102000018358 immunoglobulin Human genes 0.000 description 16
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 239000002202 Polyethylene glycol Substances 0.000 description 14
- -1 antibody Proteins 0.000 description 14
- 229940127089 cytotoxic agent Drugs 0.000 description 14
- 229920001223 polyethylene glycol Polymers 0.000 description 14
- 230000036470 plasma concentration Effects 0.000 description 13
- 231100000599 cytotoxic agent Toxicity 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 230000004614 tumor growth Effects 0.000 description 12
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 11
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 11
- 239000002254 cytotoxic agent Substances 0.000 description 11
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 201000009030 Carcinoma Diseases 0.000 description 9
- 206010061818 Disease progression Diseases 0.000 description 9
- 230000000259 anti-tumor effect Effects 0.000 description 9
- 230000005750 disease progression Effects 0.000 description 9
- 108091033319 polynucleotide Proteins 0.000 description 9
- 102000040430 polynucleotide Human genes 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 8
- 208000026310 Breast neoplasm Diseases 0.000 description 8
- 208000008839 Kidney Neoplasms Diseases 0.000 description 8
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 8
- 238000004422 calculation algorithm Methods 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000003431 cross linking reagent Substances 0.000 description 8
- 102000053180 human FOLR1 Human genes 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 230000036961 partial effect Effects 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 150000003573 thiols Chemical class 0.000 description 8
- 206010038389 Renal cancer Diseases 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 201000010982 kidney cancer Diseases 0.000 description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 7
- ANZJBCHSOXCCRQ-FKUXLPTCSA-N mertansine Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCS)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ANZJBCHSOXCCRQ-FKUXLPTCSA-N 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 201000002528 pancreatic cancer Diseases 0.000 description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 description 7
- 230000003285 pharmacodynamic effect Effects 0.000 description 7
- 230000000069 prophylactic effect Effects 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- QWPXBEHQFHACTK-KZVYIGENSA-N (10e,12e)-86-chloro-12,14,4-trihydroxy-85,14-dimethoxy-33,2,7,10-tetramethyl-15,16-dihydro-14h-7-aza-1(6,4)-oxazina-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-6-one Chemical compound CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-KZVYIGENSA-N 0.000 description 6
- 208000003174 Brain Neoplasms Diseases 0.000 description 6
- 239000004971 Cross linker Substances 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 230000002411 adverse Effects 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 210000004408 hybridoma Anatomy 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 208000029257 vision disease Diseases 0.000 description 6
- 230000004393 visual impairment Effects 0.000 description 6
- 241001529936 Murinae Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 206010047571 Visual impairment Diseases 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- 239000000611 antibody drug conjugate Substances 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 5
- 229960005558 mertansine Drugs 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 229960005489 paracetamol Drugs 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 241000894007 species Species 0.000 description 5
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 229930126263 Maytansine Natural products 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 208000009956 adenocarcinoma Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229940049595 antibody-drug conjugate Drugs 0.000 description 4
- 230000001588 bifunctional effect Effects 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 4
- 229960000520 diphenhydramine Drugs 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 125000002228 disulfide group Chemical group 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 231100000682 maximum tolerated dose Toxicity 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 231100000588 tumorigenic Toxicity 0.000 description 4
- 230000000381 tumorigenic effect Effects 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- JSHOVKSMJRQOGY-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCSSC1=CC=CC=N1 JSHOVKSMJRQOGY-UHFFFAOYSA-N 0.000 description 3
- GTBCXYYVWHFQRS-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)pentanoate Chemical compound C=1C=CC=NC=1SSC(C)CCC(=O)ON1C(=O)CCC1=O GTBCXYYVWHFQRS-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 3
- QWPXBEHQFHACTK-UHFFFAOYSA-N Maytansinol Natural products CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)C=CC=C(C)CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-UHFFFAOYSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 125000003636 chemical group Chemical group 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 238000009295 crossflow filtration Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 208000037828 epithelial carcinoma Diseases 0.000 description 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000002523 gelfiltration Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 231100001221 nontumorigenic Toxicity 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 238000011179 visual inspection Methods 0.000 description 3
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
- ORKSBKSSOSUJOY-UHFFFAOYSA-N 2,5-dioxo-1-[4-(pyridin-2-yldisulfanyl)pentanoyloxy]pyrrolidine-3-sulfonic acid Chemical compound C=1C=CC=NC=1SSC(C)CCC(=O)ON1C(=O)CC(S(O)(=O)=O)C1=O ORKSBKSSOSUJOY-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- JNWSNQJRTXEHIV-UHFFFAOYSA-N 4-(pyridin-2-yldisulfanyl)-2-sulfopentanoic acid Chemical compound OC(=O)C(S(O)(=O)=O)CC(C)SSC1=CC=CC=N1 JNWSNQJRTXEHIV-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 2
- 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 238000000729 Fisher's exact test Methods 0.000 description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000549168 Maytenus Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000001412 amines Chemical group 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- 229960004630 chlorambucil Drugs 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 239000002619 cytotoxin Substances 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 2
- 229930188854 dolastatin Natural products 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 201000010255 female reproductive organ cancer Diseases 0.000 description 2
- 102000006815 folate receptor Human genes 0.000 description 2
- 108020005243 folate receptor Proteins 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 235000004554 glutamine Nutrition 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 208000016992 lung adenocarcinoma in situ Diseases 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UOWVMDUEMSNCAV-WYENRQIDSA-N rachelmycin Chemical compound C1([C@]23C[C@@H]2CN1C(=O)C=1NC=2C(OC)=C(O)C4=C(C=2C=1)CCN4C(=O)C1=CC=2C=4CCN(C=4C(O)=C(C=2N1)OC)C(N)=O)=CC(=O)C1=C3C(C)=CN1 UOWVMDUEMSNCAV-WYENRQIDSA-N 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000000101 thioether group Chemical group 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000402 unacceptable toxicity Toxicity 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- INAUWOVKEZHHDM-PEDBPRJASA-N (7s,9s)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7-[(2r,4s,5s,6s)-5-hydroxy-6-methyl-4-morpholin-4-yloxan-2-yl]oxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1 INAUWOVKEZHHDM-PEDBPRJASA-N 0.000 description 1
- UQVNRKBFAXNOGA-LWTNMJDUSA-N (E)-tomaymycin Chemical class CO[C@H]1NC2=CC(O)=C(OC)C=C2C(=O)N2C\C(=C\C)C[C@@H]12 UQVNRKBFAXNOGA-LWTNMJDUSA-N 0.000 description 1
- DIYPCWKHSODVAP-UHFFFAOYSA-N 1-[3-(2,5-dioxopyrrol-1-yl)benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=CC(N2C(C=CC2=O)=O)=C1 DIYPCWKHSODVAP-UHFFFAOYSA-N 0.000 description 1
- SGFQCOCYZZANHV-UHFFFAOYSA-N 2-(2,5-dioxopyrrolidin-1-yl)-2-iodoacetic acid Chemical compound OC(=O)C(I)N1C(=O)CCC1=O SGFQCOCYZZANHV-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- QRYXYRQPMWQIDM-UHFFFAOYSA-N 3-benzoyl-3-(2,5-dioxopyrrol-1-yl)-1-hydroxypyrrolidine-2,5-dione Chemical compound O=C1N(O)C(=O)CC1(C(=O)C=1C=CC=CC=1)N1C(=O)C=CC1=O QRYXYRQPMWQIDM-UHFFFAOYSA-N 0.000 description 1
- NNPUPCNWEHWRPW-UHFFFAOYSA-N 4-(pyridin-2-yldisulfanyl)-2-sulfobutanoic acid Chemical compound OC(=O)C(S(O)(=O)=O)CCSSC1=CC=CC=N1 NNPUPCNWEHWRPW-UHFFFAOYSA-N 0.000 description 1
- LQILVUYCDHSGEU-UHFFFAOYSA-N 4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexane-1-carboxylic acid Chemical compound C1CC(C(=O)O)CCC1CN1C(=O)C=CC1=O LQILVUYCDHSGEU-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 241000473391 Archosargus rhomboidalis Species 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000030808 Clear cell renal carcinoma Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 208000029663 Hypophosphatemia Diseases 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 108091006036 N-glycosylated proteins Proteins 0.000 description 1
- 241000604373 Ovatus Species 0.000 description 1
- 238000012879 PET imaging Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010037508 Punctate keratitis Diseases 0.000 description 1
- 101001039269 Rattus norvegicus Glycine N-methyltransferase Proteins 0.000 description 1
- 238000012952 Resampling Methods 0.000 description 1
- 102220492414 Ribulose-phosphate 3-epimerase_H35A_mutation Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000013103 analytical ultracentrifugation Methods 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000719 anti-leukaemic effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 108010044540 auristatin Proteins 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
- 229930195731 calicheamicin Natural products 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 210000002987 choroid plexus Anatomy 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012866 crystallographic experiment Methods 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 125000005414 dithiopyridyl group Chemical group 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003118 drug derivative Substances 0.000 description 1
- 229960005501 duocarmycin Drugs 0.000 description 1
- 229930184221 duocarmycin Natural products 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000005179 haloacetyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- YACHGFWEQXFSBS-RJXCBBHPSA-N leptomycin Chemical class OC(=O)/C=C(C)/C[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)/C=C(\C)/C=C/C[C@@H](C)\C=C(/CC)\C=C\[C@@H]1OC(=O)C=C[C@@H]1C YACHGFWEQXFSBS-RJXCBBHPSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 description 1
- 235000007635 levomefolic acid Nutrition 0.000 description 1
- 239000011578 levomefolic acid Substances 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000002250 liver carcinoma Diseases 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- SVVGCFZPFZGWRG-OTKBOCOUSA-N maytansinoid dm4 Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)C(C)(C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)S)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 SVVGCFZPFZGWRG-OTKBOCOUSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 229940125645 monoclonal antibody drug Drugs 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 201000011330 nonpapillary renal cell carcinoma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000003947 protein internalization Effects 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 201000003827 punctate epithelial keratoconjunctivitis Diseases 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 201000003804 salivary gland carcinoma Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 238000012447 xenograft mouse model Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Botany (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
葉酸受容体アルファまたは葉酸結合タンパク質としても知られる葉酸受容体1(FOLR1)は、細胞の原形質膜上で発現されるN-グリコシル化タンパク質である。FOLR1は、葉酸に対して、または数個の還元葉酸誘導体に対して、高い親和性を有する。FOLR1は、生理的葉酸である5-メチルテトラヒドロ葉酸の細胞内部への送達を媒介する。
かかる癌を治療するための有望な方法として、抗体が浮上してきている。加えて、別の化合物、例えば、細胞毒素と抱合した抗体を含む免疫抱合体も、可能性のある治療薬として研究されている。具体的には、植物由来の抗真菌剤及び抗腫瘍剤であるマイタンシノイドを含む免疫抱合体は、いくらかの有益な活性を有することが示されている。メイテヌス・オバツス(Maytenus ovatus)及びメイテヌス・ブカナニ(Maytenus buchananii)のエタノール抽出物からの3種のアンサマクロライドの単離は、S.M.Kupchanらによって最初に報告され、マイクログラム/kgの用量範囲でのマウスモデルにおけるその抗白血病効果の実証と並んで、米国特許第3,896,111号の主題となっている。マイタンシノイドは、しかしながら、中枢神経障害と末梢神経障害との両方を引き起こす許容できない毒性、ならびに、特に、悪心、嘔吐、下痢、肝機能検査の上昇、及び一般的ではないが脱力及び昏睡といった副作用を有する。この全体的な毒性は、マイタンシノイドの抗体との抱合によってある程度減少し、これは、抗体抱合体が、抗原陽性細胞と比較して抗原陰性細胞に対して桁違いに低い毒性を有するためである。しかしながら、それでも、ヒトにおいて治療的に有効であるが有害作用を回避する、抗FOLR1免疫抱合体の特定の投薬レジメンを特定する必要がある。
本発明は、例えば、以下の項目を提供する。
(項目1)
FOLR1発現癌を有するヒト患者を治療するための方法であって、FOLR1ポリペプチドと結合する免疫抱合体を前記患者に投与することを含み、前記免疫抱合体が、前記患者の体重1キログラム(kg)あたり約3.0~約7ミリグラム(mg)の用量で投与され、前記患者の体重のキログラムが、調整理想体重(AIBW)に調整される、前記方法。
(項目2)
前記投与が、約90~160μg/mLのCmaxを生じさせる、項目1に記載の前記方法。
(項目3)
前記投与が、約90~150μg/mLのCmaxを生じさせる、項目2に記載の前記方法。
(項目4)
前記投与が、2700時間・μg/mL以下の曲線下面積(AUC)0~24を生じさせる、項目1~3のいずれか一項に記載の前記方法。
(項目5)
前記免疫抱合体が、約5.0mg/kgの用量で投与される、項目1~4のいずれか一項に記載の前記方法。
(項目6)
前記免疫抱合体が、約6.0mg/kgの用量で投与される、項目1~4のいずれか一項に記載の前記方法。
(項目7)
前記免疫抱合体が、約6.5mg/kgの用量で投与される、項目1~4のいずれか一項に記載の前記方法。
(項目8)
前記免疫抱合体が、3週間に1回投与される、項目1~7のいずれか一項に記載の前記方法。
(項目9)
前記免疫抱合体が、週1回投与される、項目1~4のいずれか一項に記載の前記方法。
(項目10)
FOLR1発現癌を有するヒト患者を治療するための方法であって、FOLR1ポリペプチドと結合する免疫抱合体を前記患者に投与することを含み、前記免疫抱合体が、前記患者の体重1キログラム(kg)あたり約3.0~約7ミリグラム(mg)の用量で投与され、前記投与が、約110~160μg/mLのCmaxを生じさせる、前記方法。
(項目11)
前記投与が、約110~150μg/mLのCmaxを生じさせる、項目10に記載の前記方法。
(項目12)
FOLR1発現癌を有するヒト患者を治療するための方法であって、FOLR1ポリペプチドと結合する免疫抱合体を前記患者に投与することを含み、前記免疫抱合体が、前記患者の体重1キログラム(kg)あたり約3.0~約7ミリグラム(mg)の用量で投与され、前記投与が、2700時間・μg/mL以下のAUC0~24を生じさせる、前記方法。
(項目13)
免疫抱合体が、配列番号6~9、11、及び12のCDRを含む抗体またはその抗原結合断片を含む、項目1~12のいずれか一項に記載の前記方法。
(項目14)
前記抗体がhuMov19である、項目13に記載の前記方法。
(項目15)
前記免疫抱合体がマイタンシノイドを含む、項目1~14のいずれか一項に記載の前記方法。
(項目16)
前記マイタンシノイドがDM4である、項目15に記載の前記方法。
(項目17)
前記免疫抱合体が、リンカーであるスルホ-SPDBを含む、項目1~16のいずれか一項に記載の前記方法。
(項目18)
前記免疫抱合体がIMGN853である、項目1~17のいずれか一項に記載の前記方法。
(項目19)
前記免疫抱合体が静脈内投与される、項目1~18のいずれか一項に記載の前記方法。
(項目20)
前記癌が、卵巣癌、脳癌、乳癌、子宮癌、子宮内膜癌、膵臓癌、腎臓癌、及び肺癌からなる群から選択される、項目1~19のいずれか一項に記載の前記方法。
(項目21)
前記肺癌が非小細胞肺癌である、項目20に記載の前記方法。
(項目22)
前記非小細胞肺癌が腺癌である、項目21に記載の前記方法。
(項目23)
前記卵巣癌が上皮性卵巣癌である、項目20に記載の前記方法。
(項目24)
前記卵巣癌が、白金製剤抵抗性、再発性、または不応性である、項目23に記載の前記方法。
(項目25)
前記癌が上皮性癌である、項目20に記載の前記方法。
(項目26)
前記患者から採取した試料が、免疫組織化学(IHC)によって測定した場合にFOLR1発現を呈する、項目1~25のいずれか一項に記載の前記方法。
(項目27)
前記試料が、少なくとも2不均一の染色強度を有する、項目26に記載の前記方法。
(項目28)
前記試料が、少なくとも2均一の染色強度を有する、項目26に記載の前記方法。
(項目29)
前記試料が、少なくとも3不均一の染色強度を有する、項目26に記載の前記方法。
(項目30)
前記試料が、少なくとも3均一の染色強度を有する、項目26に記載の前記方法。
(項目31)
前記患者にステロイドを投与することを更に含む、項目1~30のいずれか一項に記載の前記方法。
(項目32)
前記ステロイドがデキサメタゾンである、項目31に記載の前記方法。
(項目33)
前記投与が腫瘍サイズの減少をもたらす、項目1~32のいずれか一項に記載の前記方法。
(項目34)
前記癌が卵巣癌であり、前記投与がCA125の減少をもたらす、項目1~20、23、24、及び26~33のいずれか一項に記載の前記方法。
(項目35)
前記投与が毒性の減少をもたらす、項目1~34のいずれか一項に記載の前記方法。
(項目36)
前記毒性が眼毒性である、項目35に記載の前記方法。
(項目37)
抗癌特性を有する第2の化合物を投与することを更に含む、項目1~36のいずれか一項に記載の前記方法。
(項目38)
前記投与が、2785時間・μg/mL以下のAUC0~24を生じさせた、項目1~3、5~11、及び13~37のいずれか一項に記載の前記方法。
(項目39)
前記投与が、2741時間・μg/mL以下のAUC0~24を生じさせた、項目1~3、5~11、及び13~37のいずれか一項に記載の前記方法。
(項目40)
FOLR1発現癌を有するヒト患者を治療するための方法であって、前記患者にFOLR1ポリペプチドと結合する有効量の免疫抱合体を投与することを含み、前記投与が、2741時間・μg/mL以下のAUC0~24を生じさせる、前記方法。
(項目41)
前記投与が、160μg/mL以下のCmaxを生じさせる、項目40に記載の前記方法。
(項目42)
前記投与が、150μg/mL以下のCmaxを生じさせる、項目41に記載の前記方法。
(項目43)
免疫抱合体が、配列番号6~9、11、及び12のCDRを含む抗体またはその抗原結合断片を含む、項目40~42のいずれか一項に記載の前記方法。
(項目44)
前記抗体がhuMov19である、項目43に記載の前記方法。
(項目45)
前記免疫抱合体がマイタンシノイドを含む、項目40~44のいずれか一項に記載の前記方法。
(項目46)
前記マイタンシノイドがDM4である、項目45に記載の前記方法。
(項目47)
前記免疫抱合体が、リンカーであるスルホ-SPDBを含む、項目40~46のいずれか一項に記載の前記方法。
(項目48)
前記免疫抱合体がIMGN853である、項目40~47のいずれか一項に記載の前記方法。
(項目49)
前記免疫抱合体が静脈内投与される、項目40~48のいずれか一項に記載の前記方法。
(項目50)
前記癌が、卵巣癌、脳癌、乳癌、子宮癌、子宮内膜癌、膵臓癌、腎臓癌、及び肺癌からなる群から選択される、項目40~49のいずれか一項に記載の前記方法。
(項目51)
前記肺癌が非小細胞肺癌である、項目50に記載の前記方法。
(項目52)
前記非小細胞肺癌が腺癌である、項目51に記載の前記方法。
(項目53)
前記卵巣癌が上皮性卵巣癌である、項目50に記載の前記方法。
(項目54)
前記卵巣癌が、白金製剤抵抗性、再発性、または不応性である、項目53に記載の前記方法。
(項目55)
前記癌が上皮性癌である、項目50に記載の前記方法。
(項目56)
前記患者から採取した試料が、免疫組織化学(IHC)によって測定した場合にFOLR1発現を呈する、項目40~55のいずれか一項に記載の前記方法。
(項目57)
前記試料が、少なくとも2不均一の染色強度を有する、項目56に記載の前記方法。
(項目58)
前記試料が、少なくとも2均一の染色強度を有する、項目56に記載の前記方法。
(項目59)
前記試料が、少なくとも3不均一の染色強度を有する、項目56に記載の前記方法。
(項目60)
前記試料が、少なくとも3均一の染色強度を有する、項目56に記載の前記方法。
(項目61)
前記患者にステロイドを投与することを更に含む、項目40~60のいずれか一項に記載の前記方法。
(項目62)
前記ステロイドがデキサメタゾンである、項目61に記載の前記方法。
(項目63)
前記投与が腫瘍サイズの減少をもたらす、項目40~62のいずれか一項に記載の前記方法。
(項目64)
前記癌が卵巣癌であり、前記投与がCA125の減少をもたらす、項目40~50、53、54、及び56~63のいずれか一項に記載の前記方法。
(項目65)
前記投与が毒性の減少をもたらす、項目40~64のいずれか一項に記載の前記方法。
(項目66)
前記毒性が眼毒性である、項目65に記載の前記方法。
(項目67)
抗癌特性を有する第2の化合物を投与することを更に含む、項目40~66のいずれか一項に記載の前記方法。
(項目68)
FOLR1発現癌を有するヒト患者を治療するための方法であって、FOLR1ポリペプチドと結合する免疫抱合体を前記患者に投与することを含み、前記免疫抱合体が、4週間スケジュールに基づき3週間にわたって週1回投与される、前記方法。
(項目69)
前記免疫抱合体が、4週間スケジュールの1、8、及び15日目に投与される、項目68に記載の前記方法。
(項目70)
前記投与が、約90~160μg/mLのCmaxを生じさせる、項目68または69に記載の前記方法。
(項目71)
前記投与が、約90~150μg/mLのCmaxを生じさせる、項目70に記載の前記方法。
(項目72)
前記投与が、約110~160μg/mLのCmaxを生じさせる、項目68または69に記載の前記方法。
(項目73)
前記投与が、約110~150μg/mLのCmaxを生じさせる、項目72に記載の前記方法。
(項目74)
前記投与が、2700時間・μg/mL以下のAUC0~24を生じさせる、項目68~73のいずれか一項に記載の前記方法。
(項目75)
前記免疫抱合体が、約1.5~約6mg/kgの用量で投与される、項目68~74のいずれか一項に記載の前記方法。
(項目76)
前記免疫抱合体が、約1.5、2.0、2.5、3、3.3、4.0、4.1、4.2、5.0、5.5、または6.0mg/kgの用量で投与される、項目75に記載の前記方法。
(項目77)
前記免疫抱合体が、配列番号6~9、11、及び12のCDRを含む抗体またはその抗原結合断片を含む、項目68~76のいずれか一項に記載の前記方法。
(項目78)
前記抗体がhuMov19である、項目77に記載の前記方法。
(項目79)
前記免疫抱合体がマイタンシノイドを含む、請求68~78のいずれか一項に記載の前記方法。
(項目80)
前記マイタンシノイドがDM4である、項目79に記載の前記方法。
(項目81)
前記免疫抱合体が、リンカーであるスルホ-SPDBを含む、項目68~80のいずれか一項に記載の前記方法。
(項目82)
前記免疫抱合体がIMGN853である、項目68~81のいずれか一項に記載の前記方法。
(項目83)
前記免疫抱合体が静脈内投与される、項目68~82のいずれか一項に記載の前記方法。
(項目84)
前記癌が、卵巣癌、脳癌、乳癌、子宮癌、子宮内膜癌、膵臓癌、腎臓癌、及び肺癌からなる群から選択される、項目68~83のいずれか一項に記載の前記方法。
(項目85)
前記患者にステロイドを投与することを更に含む、項目68~84のいずれか一項に記載の前記方法。
(項目86)
前記ステロイドがデキサメタゾンである、項目85に記載の前記方法。
(項目87)
前記投与が腫瘍サイズの減少をもたらす、項目68~86のいずれか一項に記載の前記方法。
(項目88)
前記癌が卵巣癌であり、前記投与がCA125の減少をもたらす、項目68~87のいずれか一項に記載の前記方法。
(項目89)
前記投与が毒性の減少をもたらす、項目68~88のいずれか一項に記載の前記方法。
(項目90)
前記毒性が眼毒性である、項目89に記載の前記方法。
(項目91)
抗癌特性を有する第2の化合物を投与することを更に含む、項目68~90のいずれか一項に記載の前記方法。
(項目92)
FOLR1発現癌を有するヒト患者を治療するための方法であって、前記患者にFOLR1ポリペプチドと結合する免疫抱合体を投与することを含み、前記免疫抱合体が、前記患者の体重1キログラム(kg)あたり約1~約7ミリグラム(mg)の用量で投与され、前記患者の体重のキログラムが、調整理想体重に調整され、前記免疫抱合体が、4週間スケジュールに基づき3週間にわたって週1回投与される、前記方法。
(項目93)
前記免疫抱合体が、4週間のスケジュールの1、8、及び15日目に投与される、項目92に記載の前記方法。
(項目94)
前記免疫抱合体が、約1.1mg/kgの用量で投与される、項目92または93に記載の前記方法。
(項目95)
前記免疫抱合体が、約1.8mg/kgの用量で投与される、項目92または93に記載の前記方法。
(項目96)
前記免疫抱合体が、約2.5mg/kgの用量で投与される、項目92または93に記載の前記方法。
(項目97)
前記免疫抱合体が、約3.3mg/kgの用量で投与される、項目92または93に記載の前記方法。
(項目98)
前記投与が、約90~160μg/mLのCmaxを生じさせる、項目92~97のいずれか一項に記載の前記方法。
(項目99)
前記投与が、約90~150μg/mLのCmaxを生じさせる、項目98に記載の前記方法。
(項目100)
前記投与が、約110~160μg/mLのCmaxを生じさせる、項目92~99のいずれか一項に記載の前記方法。
(項目101)
前記投与が、約110~150μg/mLのCmaxを生じさせる、項目100に記載の前記方法。
(項目102)
前記投与が、2700時間・μg/mL以下のAUC0~24を生じさせる、項目92~101のいずれか一項に記載の前記方法。
(項目103)
前記免疫抱合体が、配列番号6~9、11、及び12のCDRを含む抗体またはその抗原結合断片を含む、項目92~102のいずれか一項に記載の前記方法。
(項目104)
前記抗体がhuMov19である、項目103に記載の前記方法。
(項目105)
前記免疫抱合体がマイタンシノイドを含む、請求92~104のいずれか一項に記載の前記方法。
(項目106)
前記マイタンシノイドがDM4である、項目105に記載の前記方法。
(項目107)
前記免疫抱合体が、リンカーであるスルホ-SPDBを含む、項目92~106のいずれか一項に記載の前記方法。
(項目108)
前記免疫抱合体がIMGN853である、項目92~107のいずれか一項に記載の前記方法。
(項目109)
前記免疫抱合体が静脈内投与される、項目92~108のいずれか一項に記載の前記方法。
(項目110)
前記癌が、卵巣癌、脳癌、乳癌、子宮癌、子宮内膜癌、膵臓癌、腎臓癌、及び肺癌からなる群から選択される、項目92~109のいずれか一項に記載の前記方法。
(項目111)
前記肺癌が非小細胞肺癌である、項目110に記載の前記方法。
(項目112)
前記非小細胞肺癌が腺癌である、項目111に記載の前記方法。
(項目113)
前記卵巣癌が上皮性卵巣癌である、項目110に記載の前記方法。
(項目114)
前記上皮性卵巣癌が、白金製剤抵抗性、再発性、または不応性である、項目113に記載の前記方法。
(項目115)
前記癌が上皮性癌である、項目110に記載の前記方法。
(項目116)
前記患者から採取した試料が、免疫組織化学(IHC)によって測定した場合にFOLR1発現を呈する、項目92~115のいずれか一項に記載の前記方法。
(項目117)
前記試料が、少なくとも2不均一の染色強度を有する、項目116に記載の前記方法。
(項目118)
前記試料が、少なくとも2均一の染色強度を有する、項目116に記載の前記方法。
(項目119)
前記試料が、少なくとも3不均一の染色強度を有する、項目116に記載の前記方法。
(項目120)
前記試料が、少なくとも3均一の染色強度を有する、項目116に記載の前記方法。
(項目121)
前記患者にステロイドを投与することを更に含む、項目92~120のいずれか一項に記載の前記方法。
(項目122)
前記ステロイドがデキサメタゾンである、項目121に記載の前記方法。
(項目123)
前記投与が腫瘍サイズの減少をもたらす、項目92~122のいずれか一項に記載の前記方法。
(項目124)
前記癌が卵巣癌であり、前記投与がCA125の減少をもたらす、項目92~110、113、114、及び116~123のいずれか一項に記載の前記方法。
(項目125)
前記投与が毒性の減少をもたらす、項目92~124のいずれか一項に記載の前記方法。
(項目126)
前記毒性が眼毒性である、項目125に記載の前記方法。
(項目127)
抗癌特性を有する第2の化合物を投与することを更に含む、項目92~126のいずれか一項に記載の前記方法。
(項目128)
前記免疫抱合体が、約2.8mg/kgの用量で投与される、項目92、93、及び98~127のいずれか一項に記載の前記方法。
(項目129)
前記免疫抱合体が、約3.0mg/kgの用量で投与される、項目92、93、及び98~127のいずれか一項に記載の前記方法。
(項目130)
前記免疫抱合体が、約3.75mg/kgの用量で投与される、項目92、93、及び98~127のいずれか一項に記載の前記方法。
(項目131)
前記投与が、2785時間・μg/mL以下のAUC0~24を生じさせる、項目92~101及び103~130のいずれか一項に記載の前記方法。
(項目132)
前記投与が、2741時間・μg/mL以下のAUC0~24を生じさせる、項目92~101及び103~130のいずれか一項に記載の前記方法。
I.定義
II.FOLR1結合剤
III.免疫抱合体
III.FOLR1結合剤を投与する方法
ヒト癌患者におけるIMGN853投薬試験
IMGN853は、葉酸受容体1(FOLR1)結合抗体及び強力なマイタンシノイドであるDM4を含む、抗体薬物抱合体(ADC)である。IMGN853は、各々が全体として参照により本明細書に組み込まれる、国際公開出願第WO2011/106528号、同第WO2012/135675号、及び同第WO2012/138749号、ならびに米国公開出願第2012/0009181号、同第2012/0282175号、及び同第2012/0282282号に既に記載されている。IMGN853はhuMov19-sSPDB-DM4であり、huMov19抗体は、配列番号3のアミノ酸配列を持つ可変重鎖と配列番号5のアミノ酸配列を持つ可変軽鎖とを含む。FOLR1タンパク質は、多くの固形腫瘍、特に、上皮性卵巣癌(EOC)、上皮性癌、非小細胞肺癌(NSCLC)、及び明細胞性腎細胞癌において上昇したレベルで発現される。
注入反応に対するIMGN853ステロイド系予防法
注入反応の可能性を減少させるために、以下のステロイド系予防法プロトコルのいずれかを使用することができる。
(4)注入の24時間前以内に、ステロイド(例えば、デキサメタゾン)を経口投与する。
IMGN853曝露と眼毒性との関係
実施例1及び2に記載したIMGN853プロトコルで治療した各患者について、注入終了時から開始し21日目まで継続して、各周期にわたる種々の時点にて、IMGN853の血漿濃度を測定した。薬物動態(PK)パラメータ分析により、角膜への沈着及び視力の損失を特徴とする、Cmaxと眼毒性の発生との間の明らかな関連性が特定された。統計的に有意な相関も、最初の24時間における曲線化面積(AUC0~24)によって測定した場合に、早期曝露レベルで観察された。(図2A~2Cを参照されたい。)
IMGN853の代替投薬手法
上で実施例3に記載のように、150μg/mlを超えるCmax値または2785時間*μg/mlを超えるAUC0~24値と眼毒性の発生率との間の相関は、全用量レベルにわたって観察された。加えて、初期PKパラメータ分析により、CmaxはIMGN853の用量と比例して増加したが、用量レベル内で、Cmax、AUC0~24、及び分布容積の著しい変動があったことが示された(図3)。
理想体重(IBW)
IBW(男性)=0.9H-88
IBW(女性)=0.9H-92
(式中、H=cm単位の身長)
除脂肪体重(LBW)
男性=1.10×kg単位の体重-128([kg単位の体重]2/[100×メートル単位の身長]2)
女性=1.07×kg単位の体重-148([kg単位の体重]2/[100×メートル単位の身長]2)
調整理想体重(AIBWまたはADJ)
IBW+0.4(kg単位の実体重-IBW)
体表面積(BSA)-モステラー式
BSA(m2)=(身長(cm)×体重(kg)/3600)1/2
体表面積(BSA)-ボイド式
BSA(m2)=(0.0003207×身長(cm)0.3×体重(グラム)(0.7285-(0.0188×LOG(グラム))]
IMGN853の代替スケジュール
Q3W投薬(漸増用量)後のIMGN853の密及び疎(ピーク及び全体)濃度時間プロファイルに基づく集団PKモデルを開発した。上述したIMGN853のPKは、研究した用量範囲にわたって線形であるように見える。
1~2.5mg/kgのQW(0.15mg/kgの増分で10個の用量レベル)
2~5mg/kgのQ2W(0.3mg/kgの増分で10個の用量レベル)
1~2.5mg/kgのQW×4後、Q2W×4(0.15mg/kgの増分で10個の用量レベル)
4W中1~2.5mg/kgのQW×3(0.15mg/kgの増分で10個の用量レベル)
多回用量IMGN853のインビボでの抗腫瘍活性及び予測薬物動態
雌のCD-1マウスにおいて10mg/kgの用量で静脈内投与した無傷のIMGN853抱合体の血漿濃度を、注射後の種々の時点でELISAによって決定した。非コンパーメント薬物動態分析プログラム(201)、WinNonlin、プロフェッショナルバージョン6.1(Pharsight,Mountain View,CA)の標準アルゴリズムを使用して、薬物動態(PK)分析を実施した。最大濃度(Cmax)、濃度時間曲線下総面積(AUC0~∞)、最終消失相における半減期(t1/2)、総血中クリアランス(CL)、及び定常状態での分布容積(Vss)を見積もった。投与後1~28日の濃度データを使用して、抱合体のt1/2を決定するための一次速度定数の値を評価した。投与後1~28日の濃度データを使用して、抗体のt1/2を決定するための一次速度定数の値を評価した。10mg/kgの用量で生成された測定値に基づいて、PKシミュレーションを、単回及び多回用量スケジュールの両方で、種々の用量レベルを使用して、WinNonlinによって実施した。得られたパラメータを、雌のSCIDマウスにおけるNCI-H2110(非小細胞肺癌、NSCLC)異種移植片において、種々の用量レベル及びスケジュールで、IMGN853の抗腫瘍活性と比較して評価した。
****
Claims (34)
- FOLR1ポリペプチドに結合する免疫抱合体を含む、ヒト患者におけるFOLR1発現子宮内膜癌または子宮癌の治療のための組成物であって、前記免疫抱合体が、配列番号6の可変軽鎖(VL)相補性決定領域(CDR)-1、配列番号7のVL CDR-2、配列番号8のVL CDR-3、配列番号9の可変重鎖(VH) CDR-1、配列番号11のVH CDR-2、および配列番号12のVH CDR-3を含む抗体またはその抗原結合断片と、マイタンシノイドとを含み、前記組成物が、前記患者の調整理想体重(AIBW)1キログラム(kg)あたり5ミリグラム(mg)の用量での投与のために製剤化される、組成物。
- 前記抗体またはその抗原結合断片が、配列番号10のVH CDR-2を含む、請求項1に記載の組成物。
- 前記抗体またはその抗原結合断片が、配列番号3を含む可変重鎖ドメインと配列番号4または配列番号5を含む可変軽鎖ドメインとを含む、請求項1に記載の組成物。
- 前記抗体またはその抗原結合断片が、配列番号3を含む可変重鎖ドメインと配列番号5を含む可変軽鎖ドメインとを含む、請求項3に記載の組成物。
- 前記抗体が、(i)American Type Culture Collection(ATCC)にPTA-10772として寄託されているプラスミドによってコードされる重鎖のアミノ酸配列と同一のアミノ酸配列を含む重鎖、および(ii)ATCCにPTA-10774として寄託されているプラスミドによってコードされる軽鎖のアミノ酸配列と同一のアミノ酸配列を含む軽鎖を含む、請求項1に記載の組成物。
- FOLR1ポリペプチドに結合する免疫抱合体を含む、ヒト患者におけるFOLR1発現癌の治療のための組成物であって、前記免疫抱合体が、配列番号6の可変軽鎖(VL)相補性決定領域(CDR)-1、配列番号7のVL CDR-2、配列番号8のVL CDR-3、配列番号9の可変重鎖(VH) CDR-1、配列番号10のVH CDR-2、および配列番号12のVH CDR-3を含む抗体またはその抗原結合断片と、マイタンシノイドとを含み、前記組成物が、前記患者の調整理想体重(AIBW)1キログラム(kg)あたり5ミリグラム(mg)の用量での投与のために製剤化される、組成物。
- 前記免疫抱合体が、1~10個のマイタンシノイド分子を含む、請求項1~6のいずれか一項に記載の組成物。
- 前記免疫抱合体が、2~5個のマイタンシノイド分子を含む、請求項1~6のいずれか一項に記載の組成物。
- 前記免疫抱合体が、3~4個のマイタンシノイド分子を含む、請求項1~6のいずれか一項に記載の組成物。
- 前記マイタンシノイドがDM4である、請求項1~9のいずれか一項に記載の組成物。
- スルホ-SPDBが前記マイタンシノイドと前記抗体またはその抗原結合断片とを連結する、請求項1~10のいずれか一項に記載の組成物。
- 前記患者から採取した試料が、免疫組織化学(IHC)によって測定した場合にFOLR1発現を呈する、請求項1~11のいずれか一項に記載の組成物。
- 前記試料が、少なくとも2不均一の染色強度を有する、請求項12に記載の組成物。
- 前記試料が、少なくとも2均一の染色強度を有する、請求項12に記載の組成物。
- 前記試料が、少なくとも3不均一の染色強度を有する、請求項12に記載の組成物。
- 前記試料が、少なくとも3均一の染色強度を有する、請求項12に記載の組成物。
- 前記組成物が、3週間に1回の投与のために製剤化されている、請求項1~16のいずれか一項に記載の組成物。
- 前記組成物が、1週間に1回の投与のために製剤化されている、請求項1~16のいずれか一項に記載の組成物。
- FOLR1ポリペプチドに結合する免疫抱合体を含む、ヒト患者におけるFOLR1発現癌の治療のための組成物であって、前記免疫抱合体が、DM4マイタンシノイドと、(i)配列番号3を含む可変重鎖ドメインおよび(ii)配列番号5を含む可変軽鎖ドメインを含む抗体とを含み、前記DM4マイタンシノイドが、スルホ-SPDBによって前記抗体に連結しており、前記組成物が、平均して、抗体1個あたり約1~約10個のDM4マイタンシノイドを含み、前記組成物が、前記患者の調整理想体重(AIBW)1キログラム(kg)あたり5ミリグラム(mg)の用量での3週間に1回の投与のために製剤化されている、組成物。
- 前記抗体が、(i)American Type Culture Collection(ATCC)にPTA-10772として寄託されているプラスミドによってコードされる重鎖のアミノ酸配列と同一のアミノ酸配列を含む重鎖、および(ii)ATCCにPTA-10774として寄託されているプラスミドによってコードされる軽鎖のアミノ酸配列と同一のアミノ酸配列を含む軽鎖を含む、請求項19に記載の組成物。
- 前記組成物がIV投与のために製剤化される、請求項1~20のいずれか一項に記載の組成物。
- 前記癌が子宮内膜癌である、請求項1~21のいずれか一項に記載の組成物。
- 前記癌が子宮癌である、請求項1~21のいずれか一項に記載の組成物。
- 前記癌が卵巣癌である、請求項6~21のいずれか一項に記載の組成物。
- 前記卵巣癌が上皮性卵巣癌である、請求項24に記載の組成物。
- 前記卵巣癌が、白金製剤抵抗性、再発性、または不応性である、請求項25に記載の組成物。
- 前記投与がCA125の減少をもたらす、請求項24~26のいずれか一項に記載の組成物。
- 前記癌が腹膜の癌である、請求項6~21のいずれか一項に記載の組成物。
- 前記組成物が、ステロイドと組み合わせて前記患者に投与されることを特徴とする、請求項1~28のいずれか一項に記載の組成物。
- 前記ステロイドがデキサメタゾンである、請求項29に記載の組成物。
- 前記投与が毒性の減少をもたらす、請求項1~30のいずれか一項に記載の組成物。
- 前記毒性が眼毒性である、請求項31に記載の組成物。
- 平均して、抗体1個あたり約2~約5個のDM4マイタンシノイドを含む、請求項19~32のいずれか一項に記載の組成物。
- 平均して、抗体1個あたり約3~約4個のDM4マイタンシノイドを含む、請求項19~32のいずれか一項に記載の組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023192883A JP2024016239A (ja) | 2013-10-08 | 2023-11-13 | 抗folr1免疫抱合体投薬レジメン |
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361888365P | 2013-10-08 | 2013-10-08 | |
US201361888337P | 2013-10-08 | 2013-10-08 | |
US61/888,365 | 2013-10-08 | ||
US61/888,337 | 2013-10-08 | ||
US201461948363P | 2014-03-05 | 2014-03-05 | |
US61/948,363 | 2014-03-05 | ||
US201462004815P | 2014-05-29 | 2014-05-29 | |
US62/004,815 | 2014-05-29 | ||
JP2019156399A JP2019218386A (ja) | 2013-10-08 | 2019-08-29 | 抗folr1免疫抱合体投薬レジメン |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019156399A Division JP2019218386A (ja) | 2013-10-08 | 2019-08-29 | 抗folr1免疫抱合体投薬レジメン |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023192883A Division JP2024016239A (ja) | 2013-10-08 | 2023-11-13 | 抗folr1免疫抱合体投薬レジメン |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021178847A JP2021178847A (ja) | 2021-11-18 |
JP7386208B2 true JP7386208B2 (ja) | 2023-11-24 |
Family
ID=52813740
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016521270A Active JP6463744B2 (ja) | 2013-10-08 | 2014-10-08 | 抗folr1免疫抱合体投薬レジメン |
JP2018208158A Active JP6581279B2 (ja) | 2013-10-08 | 2018-11-05 | 抗folr1免疫抱合体投薬レジメン |
JP2019156399A Withdrawn JP2019218386A (ja) | 2013-10-08 | 2019-08-29 | 抗folr1免疫抱合体投薬レジメン |
JP2021125147A Active JP7386208B2 (ja) | 2013-10-08 | 2021-07-30 | 抗folr1免疫抱合体投薬レジメン |
JP2023192883A Pending JP2024016239A (ja) | 2013-10-08 | 2023-11-13 | 抗folr1免疫抱合体投薬レジメン |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016521270A Active JP6463744B2 (ja) | 2013-10-08 | 2014-10-08 | 抗folr1免疫抱合体投薬レジメン |
JP2018208158A Active JP6581279B2 (ja) | 2013-10-08 | 2018-11-05 | 抗folr1免疫抱合体投薬レジメン |
JP2019156399A Withdrawn JP2019218386A (ja) | 2013-10-08 | 2019-08-29 | 抗folr1免疫抱合体投薬レジメン |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023192883A Pending JP2024016239A (ja) | 2013-10-08 | 2023-11-13 | 抗folr1免疫抱合体投薬レジメン |
Country Status (28)
Country | Link |
---|---|
US (2) | US20150132323A1 (ja) |
EP (2) | EP3055332B1 (ja) |
JP (5) | JP6463744B2 (ja) |
KR (7) | KR102639861B1 (ja) |
CN (1) | CN106164093A (ja) |
AU (4) | AU2014331964C1 (ja) |
BR (1) | BR112016007479A2 (ja) |
CA (1) | CA2926325C (ja) |
CY (1) | CY1122449T1 (ja) |
DK (1) | DK3055332T3 (ja) |
ES (1) | ES2759426T3 (ja) |
HK (1) | HK1226671A1 (ja) |
HR (1) | HRP20192140T1 (ja) |
HU (1) | HUE046696T2 (ja) |
IL (3) | IL298044A (ja) |
LT (1) | LT3055332T (ja) |
MX (2) | MX2016004411A (ja) |
MY (1) | MY174670A (ja) |
NZ (2) | NZ757964A (ja) |
PL (1) | PL3055332T3 (ja) |
PT (1) | PT3055332T (ja) |
RS (1) | RS59644B1 (ja) |
RU (1) | RU2696579C2 (ja) |
SG (3) | SG10201907042PA (ja) |
SI (1) | SI3055332T1 (ja) |
UA (1) | UA119541C2 (ja) |
WO (1) | WO2015054400A2 (ja) |
ZA (1) | ZA201902009B (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL290617B2 (en) | 2010-02-24 | 2023-11-01 | Immunogen Inc | Folate receptor 1 antibodies and immunoconjugates and uses thereof |
KR102101160B1 (ko) | 2011-04-01 | 2020-04-16 | 이뮤노젠 아이엔씨 | Folr1 암 치료의 효능을 증가시키기 위한 방법 |
CA2883222C (en) | 2012-08-31 | 2021-12-14 | Immunogen, Inc. | Diagnostic assays and kits for detection of folate receptor 1 |
BR112015028244A2 (pt) * | 2013-05-14 | 2017-09-19 | Immunogen Inc | Imunoconjugado que se liga ao folr1 e seu uso |
AU2014312086B2 (en) | 2013-08-30 | 2020-03-12 | Immunogen, Inc. | Antibodies and assays for detection of folate receptor 1 |
RU2749865C2 (ru) | 2015-09-17 | 2021-06-17 | Иммьюноджен, Инк. | Терапевтические комбинации, содержащие анти-folr1 иммуноконъюгаты |
JP2020519675A (ja) * | 2017-05-16 | 2020-07-02 | イミュノジェン・インコーポレーテッド | 抗folr1イムノコンジュゲートと抗pd−1抗体の組み合わせ |
US10596270B2 (en) * | 2017-09-18 | 2020-03-24 | Sutro Biopharma, Inc. | Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates |
BR112020016469A2 (pt) | 2018-03-13 | 2020-12-15 | Phanes Therapeutics, Inc. | Anticorpos do receptor anti-folato 1 e seus usos |
CN117866095A (zh) * | 2018-07-09 | 2024-04-12 | 普众发现医药科技(上海)有限公司 | 叶酸受体α特异性抗体 |
CA3138272A1 (en) | 2019-04-29 | 2020-11-05 | Immunogen, Inc. | Biparatopic fr-alpha antibodies and immunoconjugates |
WO2022256507A1 (en) * | 2021-06-04 | 2022-12-08 | Immunogen, Inc. | Treatment of cancer in patients with soluble fr-alpha |
WO2023102077A1 (en) * | 2021-12-01 | 2023-06-08 | Sutro Biopharma, Inc. | Anti-folate receptor conjugate cancer therapy |
CN116333135A (zh) * | 2021-12-24 | 2023-06-27 | 百奥泰生物制药股份有限公司 | 抗FRα抗体及其抗体药物偶联物和用途 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004518717A (ja) | 2001-02-09 | 2004-06-24 | シェーリング コーポレイション | 標的化された抗腫瘍剤送達系 |
US20120282282A1 (en) | 2011-04-04 | 2012-11-08 | Immunogen, Inc. | Methods for Decreasing Ocular Toxicity of Antibody Drug Conjugates |
WO2012135675A3 (en) | 2011-04-01 | 2012-12-06 | Immunogen, Inc. | Methods for increasing efficacy of folr1 cancer therapy |
JP2013508400A (ja) | 2009-10-21 | 2013-03-07 | イミュノジェン・インコーポレーテッド | 新規な投与レジメンおよび治療法 |
JP2013524773A (ja) | 2010-02-24 | 2013-06-20 | イミュノジェン, インコーポレイテッド | フォレート受容体1抗体及びそのイムノコンジュゲート及び使用 |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
US4563304A (en) | 1981-02-27 | 1986-01-07 | Pharmacia Fine Chemicals Ab | Pyridine compounds modifying proteins, polypeptides or polysaccharides |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
CA2076465C (en) | 1992-03-25 | 2002-11-26 | Ravi V. J. Chari | Cell binding agent conjugates of analogues and derivatives of cc-1065 |
US6706484B1 (en) | 1995-08-18 | 2004-03-16 | Morphosys Ag | Protein/(poly)peptide libraries |
EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
WO1998020932A2 (en) * | 1996-11-15 | 1998-05-22 | Baxter International Inc. | Conditioning for allogeneic stem cell transplantation |
WO2001002588A2 (en) | 1999-07-02 | 2001-01-11 | Morphosys Ag | Generation of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests |
US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
GB0202319D0 (en) | 2002-02-01 | 2002-03-20 | Calex Electronics Ltd | Apparatus |
WO2004082463A2 (en) * | 2003-03-17 | 2004-09-30 | Medical College Of Ohio | Folate receptor gene modulation for cancer diagnosis and therapy |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
KR20070072510A (ko) | 2004-08-30 | 2007-07-04 | 론자 바이올로직스 피엘씨 | 항체 정제를 위한 친화도- 및 이온 교환- 크로마토그래피 |
JP2008537778A (ja) * | 2005-03-30 | 2008-09-25 | パーデュー・リサーチ・ファウンデーション | 細胞の葉酸ビタミン受容体の定量化による癌予後診断法 |
EP1937307A4 (en) * | 2005-09-14 | 2009-05-13 | Hutchinson Fred Cancer Res | SPECIFIC ELIMINATION OF ACTIVATED IMMUNE CELLS |
EP1900752A1 (en) * | 2006-09-15 | 2008-03-19 | DOMPE' pha.r.ma s.p.a. | Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma |
US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
JP5624476B2 (ja) | 2008-01-18 | 2014-11-12 | バイオ−ラッド ラボラトリーズ インコーポレーティッド | アパタイトクロマトグラフィーによるリン酸化生体分子および非リン酸化生体分子の向上した精製法 |
WO2009094456A2 (en) * | 2008-01-22 | 2009-07-30 | Johns Hopkins University | Use of high-dose, post-transplantation oxazaphosphorine drugs for reduction of transplant rejection |
MY157165A (en) | 2008-04-30 | 2016-05-13 | Immunogen Inc | Cross-linkers and their uses |
CN102083461B (zh) | 2008-04-30 | 2014-09-17 | 伊缪诺金公司 | 有效的偶联物和亲水性连接体 |
RS58566B1 (sr) * | 2008-12-19 | 2019-05-31 | Medicis Pharmaceutical Corp | Formulacije imikuimoda niže dozne jačine i kratkih režima doziranja za lečenje aktinične keratoze |
US8530122B2 (en) | 2010-07-30 | 2013-09-10 | Konica Minolta Business Technologies, Inc. | Foil transferring face forming toner and image forming method |
MX343607B (es) * | 2010-11-05 | 2016-11-11 | Morphotek Inc | Receptor alfa de folato como marcador de diagnóstico y pronóstico para cánceres que expresan receptor alfa de folato. |
CA2883222C (en) * | 2012-08-31 | 2021-12-14 | Immunogen, Inc. | Diagnostic assays and kits for detection of folate receptor 1 |
CN113797343A (zh) * | 2013-04-08 | 2021-12-17 | 博格有限责任公司 | 使用辅酶q10联合疗法治疗癌症 |
BR112015028244A2 (pt) * | 2013-05-14 | 2017-09-19 | Immunogen Inc | Imunoconjugado que se liga ao folr1 e seu uso |
AU2014312086B2 (en) * | 2013-08-30 | 2020-03-12 | Immunogen, Inc. | Antibodies and assays for detection of folate receptor 1 |
RU2749865C2 (ru) * | 2015-09-17 | 2021-06-17 | Иммьюноджен, Инк. | Терапевтические комбинации, содержащие анти-folr1 иммуноконъюгаты |
-
2014
- 2014-10-08 KR KR1020237034405A patent/KR102639861B1/ko active IP Right Grant
- 2014-10-08 SG SG10201907042PA patent/SG10201907042PA/en unknown
- 2014-10-08 SI SI201431419T patent/SI3055332T1/sl unknown
- 2014-10-08 ES ES14852834T patent/ES2759426T3/es active Active
- 2014-10-08 MY MYPI2016000551A patent/MY174670A/en unknown
- 2014-10-08 NZ NZ757964A patent/NZ757964A/en unknown
- 2014-10-08 EP EP14852834.2A patent/EP3055332B1/en active Active
- 2014-10-08 WO PCT/US2014/059716 patent/WO2015054400A2/en active Application Filing
- 2014-10-08 EP EP19199163.7A patent/EP3653228B1/en active Active
- 2014-10-08 MX MX2016004411A patent/MX2016004411A/es unknown
- 2014-10-08 CA CA2926325A patent/CA2926325C/en active Active
- 2014-10-08 US US14/509,809 patent/US20150132323A1/en active Pending
- 2014-10-08 KR KR1020217010200A patent/KR102303874B1/ko active IP Right Grant
- 2014-10-08 SG SG11201602361UA patent/SG11201602361UA/en unknown
- 2014-10-08 KR KR1020207014364A patent/KR20200058592A/ko active Application Filing
- 2014-10-08 RS RS20191523A patent/RS59644B1/sr unknown
- 2014-10-08 KR KR1020247005572A patent/KR20240027861A/ko active Application Filing
- 2014-10-08 KR KR1020217029508A patent/KR20210118220A/ko not_active Application Discontinuation
- 2014-10-08 HU HUE14852834A patent/HUE046696T2/hu unknown
- 2014-10-08 PL PL14852834T patent/PL3055332T3/pl unknown
- 2014-10-08 RU RU2016114708A patent/RU2696579C2/ru active
- 2014-10-08 PT PT148528342T patent/PT3055332T/pt unknown
- 2014-10-08 AU AU2014331964A patent/AU2014331964C1/en active Active
- 2014-10-08 SG SG10202102555TA patent/SG10202102555TA/en unknown
- 2014-10-08 BR BR112016007479A patent/BR112016007479A2/pt not_active Application Discontinuation
- 2014-10-08 JP JP2016521270A patent/JP6463744B2/ja active Active
- 2014-10-08 UA UAA201604168A patent/UA119541C2/uk unknown
- 2014-10-08 NZ NZ718766A patent/NZ718766A/en unknown
- 2014-10-08 IL IL298044A patent/IL298044A/en unknown
- 2014-10-08 LT LTEP14852834.2T patent/LT3055332T/lt unknown
- 2014-10-08 KR KR1020227033036A patent/KR20220136468A/ko not_active Application Discontinuation
- 2014-10-08 DK DK14852834T patent/DK3055332T3/da active
- 2014-10-08 CN CN201480055444.3A patent/CN106164093A/zh active Pending
- 2014-10-08 KR KR1020167012025A patent/KR102115217B1/ko active IP Right Review Request
-
2016
- 2016-03-27 IL IL244772A patent/IL244772B/en active IP Right Grant
- 2016-04-06 MX MX2021009222A patent/MX2021009222A/es unknown
- 2016-12-19 HK HK16114409A patent/HK1226671A1/zh unknown
-
2018
- 2018-11-05 JP JP2018208158A patent/JP6581279B2/ja active Active
- 2018-12-11 AU AU2018278880A patent/AU2018278880A1/en not_active Abandoned
-
2019
- 2019-03-24 IL IL265586A patent/IL265586A/en unknown
- 2019-03-28 ZA ZA2019/02009A patent/ZA201902009B/en unknown
- 2019-08-29 JP JP2019156399A patent/JP2019218386A/ja not_active Withdrawn
- 2019-11-28 HR HRP20192140TT patent/HRP20192140T1/hr unknown
- 2019-12-02 CY CY20191101260T patent/CY1122449T1/el unknown
-
2020
- 2020-11-03 AU AU2020264270A patent/AU2020264270B2/en active Active
-
2021
- 2021-01-15 US US17/150,379 patent/US20210155688A1/en active Pending
- 2021-07-30 JP JP2021125147A patent/JP7386208B2/ja active Active
-
2023
- 2023-11-13 JP JP2023192883A patent/JP2024016239A/ja active Pending
-
2024
- 2024-03-12 AU AU2024201615A patent/AU2024201615A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004518717A (ja) | 2001-02-09 | 2004-06-24 | シェーリング コーポレイション | 標的化された抗腫瘍剤送達系 |
JP2013508400A (ja) | 2009-10-21 | 2013-03-07 | イミュノジェン・インコーポレーテッド | 新規な投与レジメンおよび治療法 |
JP2013524773A (ja) | 2010-02-24 | 2013-06-20 | イミュノジェン, インコーポレイテッド | フォレート受容体1抗体及びそのイムノコンジュゲート及び使用 |
WO2012135675A3 (en) | 2011-04-01 | 2012-12-06 | Immunogen, Inc. | Methods for increasing efficacy of folr1 cancer therapy |
US20120282282A1 (en) | 2011-04-04 | 2012-11-08 | Immunogen, Inc. | Methods for Decreasing Ocular Toxicity of Antibody Drug Conjugates |
Non-Patent Citations (2)
Title |
---|
Clinical Cancer Research,2010年,Vol.16(21),pp.5288-5295 |
Lung Cancer,2013年01月,Vol.80,pp.15-18 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7386208B2 (ja) | 抗folr1免疫抱合体投薬レジメン | |
US20220378694A1 (en) | Anti-FOLR1 Immunoconjugate Dosing Regimens | |
US20150297744A1 (en) | Anti-FOLR1 Immunoconjugate Dosing Regimens | |
RU2801307C1 (ru) | Схемы применения иммуноконъюгата анти-folr1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210730 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220823 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221011 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230222 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230418 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231012 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231113 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7386208 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |